Page 6 - Lupin

Lupin stock rallies 227% in 15 months; set to hit a new high after 9 years

Lupin hit a multi-year high of Rs 2,119, up 3 per cent in intra-day trade, inching close to its record high level of Rs 2,127 touched on October 6, 2015

Lupin stock soars: Analysts bullish on growth but valuation may cap upside

Brokerages sang in unison about Lupin's growth outlook but stayed divided on the valuation front with many calling the current trading values - a bit expensive

Lupin's shares zoom 6%, hit 52-week high on solid Q1 show; details here

Mumbai-based Lupin reported a whopping 77.2 per cent year-on-year (Y-o-Y) increase in profit after tax (PAT) for Q1FY25, reaching Rs 801 crore

Lupin Q1 result: Profit jumps 77% to Rs 801 cr on strong performance

On a sequential basis, the company exhibited a significant 122.9 per cent increase in PAT, with revenue also increasing by 12.6 per cent

Stocks To Watch On August 7: Real estate, SBI, Lupin, Tata Power, Bata

As of 6:31 AM, GIFT Nifty futures were up 84 points, trading at 24,140.5, suggesting a positive start for the Indian bourses.

Stocks to watch on August 6: RIL, Bharti Airtel, Lupin, TVS Motor, ONGC

At 6:31 AM, GIFT Nifty futures were up 197 points, trading at 24,299.5, indicating a robust gap-up opening.

Lupin Q1 Preview: Steady US sales, market share gains to boost profits

Brokerage estimates suggest that the pharma major is expected to see strong double-digit growth in the bottom line and single-digit growth in the top line year-on-year (YoY)

ICICI Bank, TCS, Grasim: 5 F&O stocks with high PCR for your watchlist

F&O trading strategy: A high OI-based PCR suggests that traders were expecting limited downside at these counters, and were comfortable writing Puts.

Lupin and Huons partner to bring novel dry eye treatment to Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free treatment for dry eye syndrome and healing corneal ulcers

Stocks to watch, July 16: Vedanta, HUL, Lupin, SpiceJet, Jio Fin Services

At 6:40 AM, GIFT Nifty futures traded steady at 24,620, indicating a subdued start for the markets.

Lupin divests women's health specialty biz in US to Evofem Biosciences

Company says divestment aligns US specialty business with therapeutic areas like respiratory, neurology

Stocks to watch, July 15: HCLTech, DMart, RVNL, IREDA, Zomato, Lupin

At 6:47 AM, GIFT Nifty futures indicated a major uptick of 91 points at 24,613, suggesting a gap-up start for the bourses

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook

Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts

Lupin stock rallies 7%, hits multi-year high on healthy earnings outlook

The management expects to sustain US business at the $200 million plus level, going ahead with the continued ramp-up of Tiotropium and new product launches in fiscal year 2024-25.

Stocks to buy and sell on July 4: Bhel, Lupin, Firstsource Solutions

Pharma index has rebounded from the key support zone and LUPIN is offering fresh buying opportunity with favorable risk to reward

Stocks to watch on June 24: Sun Pharma, Cipla, Lupin, Vedanta, Tata Steel

Stocks to watch on June 24: USFDA has issued six observations for Cipla's Goa facility following an inspection from June 10 to June 21, 2024

Lupin appoints Abdelaziz Toumi as CEO of newly established subsidiary LMS

LMS will focus on the development, manufacture, and sale of Active Pharmaceutical Ingredients (APIs) while expanding into the Contract Development and Manufacturing Operations (CDMO) business

USFDA closes inspection of Lupin's facility with zero 483 observations

The inspection of the Nagpur facility was carried out by the US drug regulator from June 10 to June 13, 2024

Lupin recalls 51k bottles of generic drug due to defective containers in US

Drug firm Lupin is recalling over 51,000 bottles of a generic antibiotic medication in the US market due to a "defective container", according to the American health regulator. The US-based arm of the drug maker is recalling 51,006 bottles of Cefdinir for Oral Suspension (250 mg/5 mL) due to "defective container: lack of seal integrity," US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Cefrine Oral Suspension is indicated for the treatment of a range of bacterial infections. The affected lot has been manufactured at Lupin's Mandideep-based plant and marketed in the US by Baltimore-based Lupin Pharmaceuticals, Inc, it said. The drug maker initiated the Class II nationwide (US) voluntary recall on May 8 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health